ESYT2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4699731	1.00	2/20
SCHEMBL16111548	1.00	2/20
SCHEMBL29358745	1.00	2/20
SCHEMBL29380618	1.00	2/20
SCHEMBL29931136	1.00	2/20
SCHEMBL4697866	0.89	2/20
SCHEMBL24532075	0.89	2/20
SCHEMBL4697696	0.86	2/20
SCHEMBL23092285	0.86	2/20
SCHEMBL24532059	0.86	2/20
SCHEMBL29688472	0.86	2/20
SCHEMBL22024695	0.86	2/20
SCHEMBL16136600	0.84	2/20
SCHEMBL24532058	0.83	2/20
SCHEMBL4699947	0.83	2/20
SCHEMBL22025026	0.82	2/20
SCHEMBL22119546	0.82	2/20
SCHEMBL24532062	0.82	2/20
SCHEMBL18804561	0.81	2/20
SCHEMBL22024561	0.81	2/20

Clinical trials — most relevant to ESYT2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK)	PHASE2/PHASE3	RECRUITING
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	ACTIVE_NOT_RECRUITING
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	COMPLETED
Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors	PHASE2/PHASE3	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
The Synapse Project	PHASE2	COMPLETED
Treatment of Temporo-Myofascial Disorder of Muscular Origin Using Botulinum Toxin: A Prospective Study	PHASE2	UNKNOWN
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy	EARLY_PHASE1	ACTIVE_NOT_RECRUITING
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation	nan	UNKNOWN
Protein Synthesis in the Brain of Patients With Fragile X Syndrome	nan	COMPLETED
Study of the Genetic Factors Involved in Autism and Related Disorders	nan	RECRUITING
Baker Gordon Syndrome Natural History Study	nan	RECRUITING
Comparing Outcomes of Theta Burst Stimulation in Depression Using Advanced PET Imaging	nan	NOT_YET_RECRUITING
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy	nan	COMPLETED
Multicenter Study of Patients With SHANK3 Mutations: Identification of Genes Modificators in Phelan-McDermid Syndrome (EUQ13)	nan	NOT_YET_RECRUITING
A Study on Psychopathological Progress of Early Schizophrenia-Like Disorder (SOPRES)	nan	UNKNOWN
Investigating Phenotypic, Epigenetic, and NeuroGenetic Traits in Rare and Ultra-rare Neurodevelopmental Disorders (Project PENGUIN)	nan	RECRUITING
STXBP1 and SYNGAP1 Related Disorders Natural History Study	nan	RECRUITING
Neurophysiologic Biomarkers in Rett Syndrome	nan	RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Novel Strategy for Early Detection of Esophageal Squamous Cell Carcinoma	nan	RECRUITING
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia	nan	UNKNOWN
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services	nan	UNKNOWN
Susceptibility Genes in Autism Spectrum Disorders	nan	COMPLETED
Brain Tissue Integrity and Autonomic Function Alterations in Childhood OSA and ADHD, and After Adenotonsillectomy.	nan	UNKNOWN
The Roles of Neutrophil Elastase in Lung Cancer	nan	UNKNOWN
Genes, Proteins, and Metabolites in Drug-resistant Epilepsy (DRE) Patients	nan	NOT_YET_RECRUITING
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy)	nan	UNKNOWN
EXOPULSE Mollii Suit, Motor Function & Multiple Sclerosis (EXOSEP 2)	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a ESYT2 binder may also engage these)

Protein	Name	Similarity
Q3TZZ7	—	0.998	Q3TZZ7 →
Q5FWL4	—	0.980	Q5FWL4 →
ESYT1	Extended synaptotagmin-1	0.978	landscape →
Q9Z1X1	—	0.975	Q9Z1X1 →
Q9ESF1	—	0.974	Q9ESF1 →
Q7ZWU7	—	0.973	Q7ZWU7 →
Q5RAG2	—	0.973	Q5RAG2 →
Q3U7R1	—	0.973	Q3U7R1 →
Q5M7N9	—	0.973	Q5M7N9 →
Q9HC10	—	0.972	Q9HC10 →
Q86SS6	—	0.971	Q86SS6 →
Q9R0N4	—	0.971	Q9R0N4 →
O08625	—	0.971	O08625 →
MAP4K2	Mitogen-activated protein kinase kinase kinase kinase 2	0.970	landscape →
Q920M7	—	0.970	Q920M7 →
A0FGR9	—	0.970	A0FGR9 →
Q6XYQ8	—	0.969	Q6XYQ8 →
Q6DN12	—	0.969	Q6DN12 →
Q9R0N9	—	0.969	Q9R0N9 →
P70268	—	0.969	P70268 →
Q5R8Q5	—	0.968	Q5R8Q5 →
Q8K394	—	0.968	Q8K394 →
P51432	—	0.968	P51432 →
A2AP18	—	0.967	A2AP18 →
Q9UPR0	—	0.967	Q9UPR0 →
Q9ERC5	—	0.967	Q9ERC5 →
Q812E4	—	0.967	Q812E4 →
Q5DTI8	—	0.966	Q5DTI8 →
Q99N48	—	0.966	Q99N48 →
Q8TDW5	—	0.966	Q8TDW5 →